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Patients were divided into 3 groups depending 
on age: <65 years, 65 to 74 years, and ≥75 years.
Postprocedural anticoagulation and optimi‑
zation of anticoagulant therapy was individual‑
ized depending on the patient’s history, contra‑
indications, risk of stroke and bleeding, and pa‑
tient or physician preferences. Transesophageal 
echocardiography at 30 days after the procedure 
was performed to monitor for postoperative leak.
Freixa et al2 reported adverse events during 
follow ‑up, based on VARC ‑2 criteria.3 In line with 
the study by Freixa et al,2 procedure efficacy to 
prevent thromboembolic events (stroke, tran‑
sient ischemic attack [TIA], and systemic embo‑
lism) was tested by comparing the actual event 
rate at follow ‑up with the event rate predicted by 
the CHA2DS2 ‑VASc score.
4 Individual patient an‑
nual risks were recorded, and the average annual 
risk for the whole study population was calculat‑
ed. The total number of thromboembolic events 
during the overall follow ‑up period was divided 
by the total number of patient‑years of follow‑
‑up and multiplied by 100 to obtain the actual 
annual rate of thromboembolism. Thromboem‑
bolism rate reduction was calculated as follows: 
(estimated% – actual% event rate) / estimated% 
event rate. Bleeding reduction rate was based 
on the HAS ‑BLED score and was assessed using 
the same method as for stroke risk reduction. 
Differences with a P value of less than 0.05 were 
considered significant.
Results LAA occlusion was performed in 139 pa‑
tients. At the time of the procedure, 82 patients 
were aged 64 years or younger, 44 patients were 
aged 65 to 74 years, and 13 patients were aged 
75 or older (P <0.001). Patients aged 75 years 
Introduction In patients with nonvalvular atrial 
fibrillation (AF), age is a nonmodifiable risk fac‑
tor for thromboembolism, based on the CHA2DS2‑
‑VASc score (congestive heart failure, hyperten‑
sion, age >75 years, diabetes mellitus, history of 
stroke or thromboembolism, vascular disease, 
age 65 to 74 years, female sex), and for bleeding, 
based on the HAS ‑BLED score (hypertension, ab‑
normal liver function, history of stroke or throm‑
boembolism, history of bleeding, age ≥65 years, 
use of nonsteroidal anti‑inflammatory drugs, and 
alcohol abuse). Also, the prevalence of AF increas‑
es with age, from 0.5% among patients aged 50 to 
59 years to 10% among those aged over 80 years. 
Therefore, nonvalvular AF is one of the most sig‑
nificant causes of embolic stroke in people over 
75 years of age.1
Left atrial appendage (LAA) occlusion is an al‑
ternative treatment for the prevention of stroke 
and systemic thromboembolism in patients with 
nonvalvular AF. Previous studies showed that LAA 
occlusion procedures are efficacious, safe, and 
widely performed in clinical practice. However, 
there is concern that elderly patients are more 
susceptible to complications, and thus the risk 
of performing LAA occlusion in elderly patients 
may be too high.
In this study, we present long ‑term results of 
stroke and bleeding reduction after LAA occlu‑
sion based on the patient’s age.
Material and methods A retrospective, single‑
‑center study was performed in 139 consecutive 
patients with nonvalvular AF, who underwent 
LAA occlusion with the LARIAT device (Sentre‑
HEART Inc, Redwood, California, United States). 
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Discussion Previous studies on LAA occlusion 
procedure have included patients aged under 
75 years, but few examined the safety and ef‑
ficacy of LAA occlusion in patients older than 
75 years.2,5,6 Compared with previous studies, 
our results are remarkable for 2 reasons. Firstly, 
all previous studies presented the results of LAA 
occlusion using a variety of endocardial devic‑
es,2,6 except Gafoor et al,5 who used the LARIAT 
device in only 5% of patients. We are the first to 
present the results of the LAA occlusion proce‑
dure using LARIAT in elderly patients. Second‑
ly, we present the longest follow ‑up period after 
LAA occlusion in elderly patients.
Our long ‑term follow ‑up results showed a sim‑
ilar reduction in thromboembolic risk after LAA 
occlusion in all 3 age groups. The results were sim‑
ilar to those reported in previous studies.2,5,6 Of 
note, both the CHADS2 and CHA2DS2 ‑VASc scores 
were significantly higher in patients aged 75 years 
or older, who had no thromboembolic complica‑
tions. Therefore, based on the estimated throm‑
boembolic risks according to the CHA2DS2 ‑VASc 
score, patients aged 75 years or older present 
the highest reduction in relative risk for throm‑
boembolism compared with the general popula‑
tion (FIGURE 1). These results correlate with data 
from the study by Freixa et al.2
It should be also noted that incomplete liga‑
tion and size of the leak after LAA occlusion with 
LARIAT had no clinical significance for develop‑
ing thrombosis or stroke. Two diagnosed throm‑
bi and stroke in our study were found in patients 
with complete LAA closure with no significant dif‑
ferences in patient age. Similar results were ob‑
tained in the LAA occlusion procedure with en‑
docardial devices.2,7
The relative bleeding risk reduction was re‑
duced in all 3 groups, which is similar to findings 
from previous studies.2,5,6 As expected, the lowest 
reduction was observed in patients aged 75 years 
or older (FIGURE 1). Importantly, there were no sig‑
nificant differences in antithrombotic treatments 
or older had a higher risk of stroke based on 
the CHADS2 and CHA2DS2 ‑VASc scores (3.2 and 
4.8, respectively) compared with patients aged 
64 years or younger (1.2 and 1.9, respectively) 
and those aged 65 to 74 years (2.6 and 4.3, re‑
spectively) (P = 0.001 and P = 0.001, respective‑
ly). Patients aged 65 to 74 years had the highest 
risk of bleeding based on the HAS ‑BLED score 
(3.8), as compared with those aged 64 years or 
younger (2.6) and those aged 75 years or older 
(3.6) (P = 0.001 for all comparisons). Patients aged 
65 to 74 years had also the highest proportion of 
females (P <0.001) and of patients with a previ‑
ous stroke / TIA (P = 0.03). There were no signif‑
icant differences in other comorbidities, stroke 
risk factors, antithrombotic treatment, or LAA 
dimensions. Transesophageal echocardiography 
performed 30 days postprocedure showed no sig‑
nificant differences in the prevalence of postop‑
erative leak.
One year after the procedure, 12 patients were 
lost to follow ‑up. Overall, the follow ‑up study 
population was 530.1 patient‑years. The overall 
follow ‑up of the study population was 50 months 
in patients aged 64 years or younger, 51 months 
in those aged 65 to 74 years, and 54.5 months in 
those aged 75 years or older. There were no differ‑
ences in antithrombotic treatments after follow‑
‑up (P = 0.25).
During follow ‑up, 2 cardiovascular deaths oc‑
curred, which were unrelated to the procedure, 
2 episodes of serious bleeding, and 1 episode of 
stroke. There were 2 thrombi in the LAA diag‑
nosed by follow ‑up echocardiography. These were 
successfully managed with unfractionated hepa‑
rin with no further complications. All reported 
events were included in the analysis of this study.
There were no significant differences between 
groups with regards to mortality, thromboem‑
bolic events (stroke / TIA, systemic embolism), 
and bleeding. The overall estimated annual risk 
reduction of thromboembolic events and major 
bleeding was 81% and 86%, respectively (FIGURE 1).
FIGURE 1 Effectiveness  of left atrial appendage occlusion in stroke and bleeding risk reduction (100 patient ‑years) during the overall follow ‑up in the 
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Conclusions Our results suggest that LAA occlu‑
sion with LARIAT has a similar safety endpoint 
and long ‑term efficacy in elderly patients as LAA 
occlusion in the general population. Moreover, 
it  is associated with similar stroke and bleeding 
rates, as well as similar mortality rates, regard‑
less of age. Finally, estimated thromboembolic 
and bleeding risk reductions were observed in 
all 3 age groups.
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after follow ‑up. The study by Freixa et al2 showed 
no significant differences in bleeding rates among 
patients aged 75 years or older and those young‑
er than 75 years despite higher HAS ‑BLED scores 
in the older group. In our study, there were no 
significant differences in bleeding rates; howev‑
er, the bleeding rate in patients aged 75 years or 
older was higher in our study than that report‑
ed by Freixa et al2 (8.3% and 2.3%, respectively). 
Several mechanisms significantly increase 
the risk of bleeding in elderly patients.4 The great‑
est benefits from oral anticoagulation (OAC) are 
observed in elderly and high ‑risk patients, al‑
though OAC also increases the risk of serious 
bleeding with age.4,8 Optimal international nor‑
malized ratio control in elderly patients is difficult 
to achieve, and almost 50% of older patients do 
not reach a therapeutic range. In contrast to vi‑
tamin K antagonists, non–vitamin K antagonist 
oral anticoagulants are reported to have a shorter 
half ‑life; moreover, they slightly reduce the risk of 
hemorrhagic bleeding but are not free from com‑
plications.9 Of note, more than 20% of patients 
with nonvalvular AF receive inappropriate anti‑
thrombotic therapy.10 Elderly patients also have 
a higher frequency of comorbidities that increase 
the risk of bleeding, such as hypertension, liver 
failure, renal insufficiency, anemia, malignan‑
cy, or coronary artery disease with concomitant 
antiplatelet therapy.4 In our study, all bleeding 
events were intracranial; 3 patients were on an‑
ticoagulation therapy and 1 event was due to un‑
controlled hypertension.
In our previous study, we showed that LAA oc‑
clusion with LARIAT is a safe procedure with high 
success rates.11,12 Long ‑term follow ‑up shows no 
differences in mortality due to cardiovascular and 
noncardiovascular causes. Our results correlate 
with data from other studies2,6; however, the mor‑
tality rate in our group was lower compared with 
that reported by Davtyan et al.6 Due to natural 
outcomes, mortality rate in patients aged 75 years 
or older was higher compared with the other age 
groups, but this difference was not significant. 
Thus, overall the LAA occlusion procedure has 
no effect on mortality regardless of patient age.
Study limitations This was a nonrandomized, ret‑
rospective, observational study of procedures per‑
formed by one experienced operator. The major 
limitation for estimating the overall value of LAA 
occlusion is the lack of a control group and only 
a calculated stroke or bleeding risk. Also, 12 pa‑
tients were lost to follow ‑up after 1 year (8.6%). 
Another limitation were unequally sized groups. 
Long ‑term results for thromboembolic event re‑
duction are confounded by the high proportion of 
patients on OAC at the time of their last follow‑
‑up visit. Several antithrombotic drugs with dif‑
ferent pharmacological properties and indications 
were prescribed; however, there were no signifi‑
cant differences between the groups.
